血流感染症検査市場規模、シェア、動向分析レポート：製品タイプ別、サンプルタイプ別、技術別、最終用途別、地域別、セグメント別予測、2023～2030年

血流感染症検査市場の成長と動向：

Grand View Research, Inc.の最新調査によると、世界の血流感染症検査市場規模は2030年までに9億7,757万米ドルに達し、CAGR 4.5%で推移すると予測されています。

世界の感染症の増加、感染管理に対する意識の高まりと重視は、市場を牽引する主な要因の一部です。例えば、欧州疾病予防管理センター（ECDC）が2022年4月に実施した疫学調査によると、欧州全域でカンジダ・オーリスの症例が顕著に増加しています。この調査では、2020年には8カ国から335症例が報告されていたC. aurisの報告症例が、2021年には13カ国から655症例が報告され、大幅に増加していることが明らかになっています。2021年に報告された症例の15.3％は血流感染症でした。

加えて、市場の主要企業による技術の進歩や新製品の発売の増加、政府の奨励的な取り組み、献血の重要性に関する意識の高まりが、市場の成長を促進すると予想されます。例えば、2020年4月。次世代シーケンサー企業のDNAe社は、革新的なLiDia-SEQプラットフォームと最初のアッセイについて、米国食品医薬品局（FDA）から「画期的デバイス（Breakthrough Device）」の指定を受けた。この指定により、DNAe社は、感染症診断、がん、感染管理、パンデミックへの備えと対応に向けた迅速で費用対効果の高い検査を開発することが可能になります。指定された検査法は、感染症、特に血流感染症（BSI）と抗菌薬耐性（AMR）に焦点を当て、患者の検体から直接、敗血症に関連する感染症を検出・同定することを目的としています。FDAはBreakthrough Deviceプログラムを通じて、DNAeのLiDia-SEQシーケンスシステムとBSI/AMR検査の開発と上市を促進するための継続的な支援と協力的な交流を提供します。

F. Hoffmann-La Roche Ltd、bioMerieux SA、BDなど、市場の主要企業は、製品能力を強化し、製品提供を促進するために合併・買収戦略を実施しています。例えば、2021年5月、F. Hoffmann-La Roche LtdはGenMark Diagnosticsを18億米ドルで買収しました。この買収により、Rocheは分子診断薬のポートフォリオを拡大することになります。同様に、2021年12月、同社はTIB Molbiol Groupを買収しました。TIB Molbiol Groupは、血液学検査、遺伝性遺伝子検査、感染症診断、移植医療向けに約45のCE-IVD承認アッセイを有しています。

血流感染症検査市場レポートハイライト

• 製品別では、試薬・消耗品セグメントが2022年の市場で最大の売上シェアを占めました。また、このセグメントは、ドナーおよびレシピエントがスクリーニング製品を容易に入手でき、頻繁に購入できることから、予測期間中に最も速い速度で成長すると予測されています。
• サンプルタイプに基づくと、血液培養セグメントは2022年に最大の収益シェアを占め、予測期間中に最も速いCAGRを示す見込みです。
• 技術別では、PCR分野が2022年に市場で最大の収益シェアを占め、検査需要の増加により予測期間中に最も速いCAGRで成長すると予測されています。
• 最終用途別では、病院・診断センターセグメントが2022年に最大の収益シェアを占めました。
• 北米は血流感染症検査市場を独占し、2022年に最大の収益シェアを占めました。これは、この地域の可処分所得の増加、高度に発達した医療インフラ、有利な償還政策によるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/付随市場の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 業界分析ツール
  • ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19感染症の影響分析

第4章 血流感染症検査市場：製品ビジネス分析

• 血流感染症検査市場：製品の変動分析
• 装置
• 試薬および消耗品

第5章 血流感染症検査市場：サンプルタイプのビジネス分析

• 血流感染症検査市場：サンプルタイプの変動分析
• 全血
• 血液培養

第6章 血流感染症検査市場：技術のビジネス分析

• 血流感染症検査市場：技術の変動分析
• PCR
• 質量分析
• In situハイブリダイゼーション
• その他

第7章 血流感染症検査市場：エンドユーザーのビジネス分析

• 血流感染症検査市場：エンドユーザーの変動分析
• 病院と診断センター
• カスタムラボサービスプロバイダー
• 学術研究機関
• その他

第8章 血流感染症検査市場：地域ビジネス分析

• 地域別血流感染症検査市場シェア、2022年と2030年
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第9章 血流感染症検査市場：競合情勢

• 参入企業
• 参入企業概要
• 企業の市場シェア分析、2022年
• 戦略マッピング

第10章 アナリストの視点

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 Global Bloodstream Infection Testing Market, By Product, 2018 - 2030 (USD Million)
• Table 4 Global Bloodstream Infection Testing Market, By Sample type, 2018 - 2030 (USD Million)
• Table 5 Global Bloodstream Infection Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 6 Global Bloodstream Infection Testing Market, By End-user, 2018 - 2030 (USD Million)
• Table 7 Global Bloodstream Infection Testing Market, By Region, 2018 - 2030 (USD Million)
• Table 8 North America Bloodstream Infection Testing Market, By Country, 2018 - 2030 (USD Million)
• Table 9 North America Bloodstream Infection Testing Market, By Product, 2018 - 2030 (USD Million)
• Table 10 North America Bloodstream Infection Testing Market, By Sample type, 2018 - 2030 (USD Million)
• Table 11 North America Bloodstream Infection Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 12 North America Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 13 U.S. Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 14 U.S. Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 15 U.S. Bloodstream Infection Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 16 U.S. Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 17 Canada Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 18 Canada Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 19 Canada Bloodstream Infection Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 20 Canada Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD million)
• Table 21 Europe Bloodstream Infection Testing market, by Country, 2018 - 2030 (USD Million)
• Table 22 Europe Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 23 Europe Bloodstream Infection Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 24 Europe Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 25 Europe Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 26 UK Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 27 UK. Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 28 UK Bloodstream Infection Testing Market, By Technology, 2018 - 2030 (USD Million)
• Table 29 UK Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 30 Germany Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 31 Germany Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 32 Germany Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 33 Germany Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 34 France Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 35 France Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 36 France Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 37 France Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 38 Italy Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 39 Italy Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 40 Italy Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 41 Italy Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 42 Spain Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 43 Spain Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 44 Spain Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 45 Spain Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 46 Denmark Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 47 Denmark Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 48 Denmark Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 49 Denmark Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 50 Sweden Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 51 Sweden Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 52 Sweden Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 53 Sweden Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 54 Norway Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 55 Norway Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 56 Norway Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 57 Norway Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 58 Asia Pacific Bloodstream Infection Testing market, by Country, 2018 - 2030 (USD Million)
• Table 59 Asia Pacific Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 60 Asia Pacific Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 61 Asia Pacific Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 62 Asia Pacific Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 63 Japan Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 64 Japan Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 65 Japan Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 66 Japan Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 67 China Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 68 China Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 69 China Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 70 China Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 71 India Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 72 India Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 73 India Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 74 India Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 75 Australia Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 76 Australia Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 77 Australia Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 78 Australia Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 79 Thailand Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 80 Thailand Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 81 Thailand Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 82 Thailand Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 83 South Korea Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 84 South Korea Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 85 South Korea Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 86 South Korea Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 87 Latin America Bloodstream Infection Testing market, by Country, 2018 - 2030 (USD Million)
• Table 88 Latin America Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 89 Latin America Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 90 Latin America Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 91 Latin America Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 92 Brazil Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 93 Brazil Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 94 Brazil Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 95 Brazil Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 96 Mexico Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 97 Mexico Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 98 Mexico Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 99 Mexico Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 100 Argentina Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 101 Argentina Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 102 Argentina Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 103 Argentina Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 104 Middle East & Africa Bloodstream Infection Testing market, by Country, 2018 - 2030 (USD Million)
• Table 105 Middle East & Africa Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 106 Middle East & Africa Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 107 Middle East & Africa Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 108 Middle East & Africa Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 109 South Africa Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 110 South Africa Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 111 South Africa Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 112 South Africa Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 113 Saudi Arabia Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 114 Saudi Arabia Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 115 Saudi Arabia Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 116 Saudi Arabia Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 117 UAE Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 118 UAE Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 119 UAE Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 120 UAE Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)
• Table 121 Kuwait Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
• Table 122 Kuwait Bloodstream Infection Testing market, by Sample type, 2018 - 2030 (USD Million)
• Table 123 Kuwait Bloodstream Infection Testing market, by Technology, 2018 - 2030 (USD Million)
• Table 124 Kuwait Bloodstream Infection Testing market, by End-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 Market formulation & validation
• Fig. 7 Microscope software, market segmentation
• Fig. 8 Market snapshot, 2022
• Fig. 9 Market Trends & Outlook
• Fig. 10 Market driver relevance analysis (current & future impact)
• Fig. 11 Market restraint relevance analysis (current & future impact)
• Fig. 12 Market challenge relevance analysis (current & future impact)
• Fig. 13 SWOT analysis
• Fig. 14 Porter's five forces analysis
• Fig. 15 Global bloodstream infection testing market: product movement & market share analysis.
• Fig. 16 Global bloodstream infection testing market, for reagents and consumables, 2018 - 2030 (USD Million)
• Fig. 17 Global bloodstream infection testing market, for instruments, 2018 - 2030 (USD Million)
• Fig. 18 Global bloodstream infection testing market: Sample type movement & market share analysis.
• Fig. 19 Global bloodstream infection testing market, for whole blood, 2018 - 2030 (USD Million)
• Fig. 20 Global bloodstream infection testing market, for blood culture, 2018 - 2030 (USD Million)
• Fig. 21 Global bloodstream infection testing market: Technology movement & market share analysis.
• Fig. 22 Global bloodstream infection testing market, for PCR, 2018 - 2030 (USD Million)
• Fig. 23 Global bloodstream infection testing market, for mass spectroscopy, 2018 - 2030 (USD Million)
• Fig. 24 Global bloodstream infection testing market, for in situ hybridization, 2018 - 2030 (USD Million)
• Fig. 25 Global bloodstream infection testing market, for others, 2018 - 2030 (USD Million)
• Fig. 26 Global bloodstream infection testing market: End-use movement & market share analysis.
• Fig. 27 Global bloodstream infection testing market, for end-use, movement & market share analysis.
• Fig. 28 Global bloodstream infection testing market, for hospitals & diagnostic centers, 2018 - 2030 (USD Million)
• Fig. 29 Global bloodstream infection testing market, for custom laboratory service providers, 2018 - 2030 (USD Million)
• Fig. 30 Global bloodstream infection testing market, for academic & research institutes, 2018 - 2030 (USD Million)
• Fig. 31 Global bloodstream infection testing market, for others, 2018 - 2030 (USD Million)
• Fig. 32 Regional marketplace: key takeaways
• Fig. 33 Regional outlook, 2022 & 2030
• Fig. 34 Global bloodstream infection testing market: region movement analysis.
• Fig. 35 North America bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 36 U.S. key country dynamics
• Fig. 37 U.S. bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 38 Canada key country dynamics
• Fig. 39 Canada bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 40 Europe bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 41 UK key country dynamics
• Fig. 42 UK bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 43 Germany key country dynamics
• Fig. 44 Germany bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 45 France key country dynamics
• Fig. 46 France bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 47 Italy key country dynamics
• Fig. 48 Italy bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 49 Spain key country dynamics
• Fig. 50 Spain bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 51 Denmark key country dynamics
• Fig. 52 Denmark bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 53 Sweden key country dynamics
• Fig. 54 Sweden bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 55 Norway key country dynamics
• Fig. 56 Norway bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 57 Asia Pacific bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 58 Japan key country dynamics
• Fig. 59 Japan bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 60 China key country dynamics
• Fig. 61 China bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 62 India key country dynamics
• Fig. 63 India bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 64 Australia key country dynamics
• Fig. 65 Australia bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 66 Thailand key country dynamics
• Fig. 67 Thailand bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 68 South Korea key country dynamics
• Fig. 69 South Korea bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 70 Latin America bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 71 Brazil key country dynamics
• Fig. 72 Brazil bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 73 Mexico key country dynamics
• Fig. 74 Mexico bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 75 Argentina key country dynamics
• Fig. 76 Argentina bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 77 Middle East and Africa bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 78 South Africa key country dynamics
• Fig. 79 South Africa bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 80 Saudi Arabia key country dynamics
• Fig. 81 Saudi Arabia bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 82 UAE key country dynamics
• Fig. 83 UAE bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 84 Kuwait key country dynamics
• Fig. 85 Kuwait bloodstream infection testing market, 2018 - 2030 (USD Million)
• Fig. 86 Company market position analysis
• Fig. 87 Company/competition categorization
• Fig. 88 Strategy mapping

Bloodstream Infection Testing Market Growth & Trends:

The global bloodstream infection testing market size is expected to reach USD 977.57 million by 2030, registering at a CAGR of 4.5%, according to a new study by Grand View Research, Inc. The increasing number of infectious diseases globally and the growing awareness and emphasis on infection control are some of the major factors driving the market. For Instance, according to an epidemiologic survey organized by the European Centre for Disease Prevention and Control (ECDC) in April 2022, there was a notable increase in Candida auris cases across the European region. The survey revealed a significant rise in reported cases of C. auris, from 335 cases reported by 8 countries in 2020 to 655 cases reported by 13 countries in 2021. Bloodstream infections accounted for 15.3% of the reported cases in 2021.

In addition, increasing technological advancements and new product launches by key companies in the market, encouraging government initiatives, and increasing awareness about the importance of blood donation are expected to propel market growth. For instance, in April 2020. DNAe, a next-generation sequencing company, has received a "Breakthrough Device" designation from the U.S. Food and Drug Administration (FDA) for its innovative LiDia-SEQ platform and first assay. This designation enables DNAe to develop rapid and cost-effective tests for infectious disease diagnostics, cancer, infection control, and pandemic preparedness and response. The designated assay focuses on infectious diseases, specifically bloodstream infections (BSI) and antimicrobial resistance (AMR), aiming to detect and identify infections associated with sepsis directly from patient specimens. Through the Breakthrough Device program, the FDA will provide ongoing support and collaborative interactions to facilitate the development and launch of DNAe's LiDia-SEQ sequencing system and BSI/AMR test.

The key players in the market, such as F. Hoffmann-La Roche Ltd., bioMerieux SA, BD, etc., are implementing the strategy of merger & acquisition to enhance product capabilities and promote their product offerings. For instance, in May 2021, F. Hoffmann-La Roche Ltd. completed the acquisition of GenMark Diagnostics for USD 1.8 billion. This acquisition would help Roche expand its molecular diagnostics portfolio. Similarly, in December 2021, the company acquired TIB Molbiol Group, which has around 45 CE-IVD-approved assays for hematology testing, inherited genetic testing, diagnosing infectious diseases, and transplant medicine.

Bloodstream Infection Testing Market Report Highlights:

• Based on the product, the reagents and consumables segment accounted for the largest revenue share of the market in 2022. The segment is also expected to grow at the fastest rate over the forecast period owing to the easy availability and frequent purchase of screening products for donors and recipients
• Based on sample type, the blood culture segment accounted for the largest revenue share in 2022 and is expected to witness the fastest CAGR over the forecast period
• Based on technology, the PCR segment held the largest revenue share of the market in 2022 and is expected to grow with the fastest CAGR over the forecast period owing to increasing demand for the tests
• Based on end-user, the hospital and diagnostic centers segment accounted for the largest revenue share in 2022
• North America dominated the bloodstream infection testing market and accounted for the largest revenue share in 2022. This is due to the region's Increasing disposable income, highly developed health infrastructure, and favorable reimbursement policies

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Sample Type segment
    • 1.1.1.2. Product segment
    • 1.1.1.3. Technology segment
    • 1.1.1.4. End-use segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Product and Sample Type Snapshot
• 2.3. Technology and End-use Snapshot
• 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of infectious diseases
    • 3.2.1.2. Technological advancements in bloodstream infection testing
    • 3.2.1.3. Growing initiatives for blood donations campaign
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High diagnosis cost and lower investments in underdeveloped countries
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Bloodstream Infection Testing Market: Product Business Analysis

• 4.1. Bloodstream Infection Testing Market: Product Movement Analysis
• 4.2. Instruments
  • 4.2.1. Instruments Market, 2018 - 2030 (USD Million)
• 4.3. Reagents and Consumables
  • 4.3.1. Reagents and Consumables Market, 2018 - 2030 (USD Million)

Chapter 5. Bloodstream Infection Testing Market: Sample Type Business Analysis

• 5.1. Bloodstream Infection Testing Market: Sample Type Movement Analysis
• 5.2. Whole Blood
  • 5.2.1. Whole Blood Market, 2018 - 2030 (USD Million)
• 5.3. Blood Culture
  • 5.3.1. Blood Culture Market, 2018 - 2030 (USD Million)

Chapter 6. Bloodstream Infection Testing Market: Technology Business Analysis

• 6.1. Bloodstream Infection Testing Market: Technology Movement Analysis
• 6.2. PCR
  • 6.2.1. PCR Market, 2018 - 2030 (USD Million)
• 6.3. Mass Spectroscopy
  • 6.3.1. Mass Spectroscopy Market, 2018 - 2030 (USD Million)
• 6.4. In Situ Hybridization
  • 6.4.1. In Situ Hybridization Market, 2018 - 2030 (USD Million)
• 6.5. Others
  • 6.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Bloodstream Infection Testing Market: End-User Business Analysis

• 7.1. Bloodstream Infection Testing Market: End-User Movement Analysis
• 7.2. Hospitals & Diagnostic Centers
  • 7.2.1. Hospitals & Diagnostics Centers Market, 2018 - 2030 (USD Million)
• 7.3. Custom Laboratory Service Providers
  • 7.3.1. Custom Laboratory Service Providers Market, 2018 - 2030 (USD Million)
• 7.4. Academic & Research Institutes
  • 7.4.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
• 7.5. Others
  • 7.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Bloodstream Infection Testing Market: Regional Business Analysis

• 8.1. Bloodstream Infection Testing Market Share By Region, 2022 & 2030
• 8.2. North America
  • 8.2.1. SWOT Analysis
  • 8.2.2. North America Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.2.3. U.S.
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Target Disease Prevalence
    • 8.2.3.3. Competitive Scenario
    • 8.2.3.4. Regulatory Framework
    • 8.2.3.5. Reimbursement Scenario
    • 8.2.3.6. U.S. Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.2.4. Canada
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Target Disease Prevalence
    • 8.2.4.3. Competitive Scenario
    • 8.2.4.4. Regulatory Framework
    • 8.2.4.5. Reimbursement Scenario
    • 8.2.4.6. Canada Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Target Disease Prevalence
    • 8.3.2.3. Competitive Scenario
    • 8.3.2.4. Regulatory Framework
    • 8.3.2.5. Reimbursement Scenario
    • 8.3.2.6. UK Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.3.3. Germany
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Target Disease Prevalence
    • 8.3.3.3. Competitive Scenario
    • 8.3.3.4. Regulatory Framework
    • 8.3.3.5. Reimbursement Scenario
    • 8.3.3.6. Germany Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Target Disease Prevalence
    • 8.3.4.3. Competitive Scenario
    • 8.3.4.4. Regulatory Framework
    • 8.3.4.5. Reimbursement Scenario
    • 8.3.4.6. France Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Target Disease Prevalence
    • 8.3.5.3. Competitive Scenario
    • 8.3.5.4. Regulatory Framework
    • 8.3.5.5. Reimbursement Scenario
    • 8.3.5.6. Italy Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Target Disease Prevalence
    • 8.3.6.3. Competitive Scenario
    • 8.3.6.4. Regulatory Framework
    • 8.3.6.5. Reimbursement Scenario
    • 8.3.6.6. Spain Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Target Disease Prevalence
    • 8.3.7.3. Competitive Scenario
    • 8.3.7.4. Regulatory Framework
    • 8.3.7.5. Reimbursement Scenario
    • 8.3.7.6. Denmark Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Target Disease Prevalence
    • 8.3.8.3. Competitive Scenario
    • 8.3.8.4. Regulatory Framework
    • 8.3.8.5. Reimbursement Scenario
    • 8.3.8.6. Sweden Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Target Disease Prevalence
    • 8.3.9.3. Competitive Scenario
    • 8.3.9.4. Regulatory Framework
    • 8.3.9.5. Reimbursement Scenario
    • 8.3.9.6. Norway Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Competitive Scenario
    • 8.4.2.4. Regulatory Framework
    • 8.4.2.5. Reimbursement Scenario
    • 8.4.2.6. Japan Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Competitive Scenario
    • 8.4.3.4. Regulatory Framework
    • 8.4.3.5. Reimbursement Scenario
    • 8.4.3.6. China Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Competitive Scenario
    • 8.4.4.4. Regulatory Framework
    • 8.4.4.5. Reimbursement Scenario
    • 8.4.4.6. India Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.4.5. Australia
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Target Disease Prevalence
    • 8.4.5.3. Competitive Scenario
    • 8.4.5.4. Regulatory Framework
    • 8.4.5.5. Reimbursement Scenario
    • 8.4.5.6. Australia Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.4.6. Thailand
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Target Disease Prevalence
    • 8.4.6.3. Competitive Scenario
    • 8.4.6.4. Regulatory Framework
    • 8.4.6.5. Reimbursement Scenario
    • 8.4.6.6. Thailand Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.4.7. South Korea
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Target Disease Prevalence
    • 8.4.7.3. Competitive Scenario
    • 8.4.7.4. Regulatory Framework
    • 8.4.7.5. South Korea Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Competitive Scenario
    • 8.5.2.4. Regulatory Framework
    • 8.5.2.5. Reimbursement Scenario
    • 8.5.2.6. Brazil Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.5.3. Mexico
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. Regulatory Framework
    • 8.5.3.5. Reimbursement Scenario
    • 8.5.3.6. Mexico Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.5.4. Argentina
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Competitive Scenario
    • 8.5.4.4. Regulatory Framework
    • 8.5.4.5. Reimbursement Scenario
    • 8.5.4.6. Argentina Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
• 8.6. MEA
  • 8.6.1. MEA Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Competitive Scenario
    • 8.6.2.4. Regulatory Framework
    • 8.6.2.5. Reimbursement Scenario
    • 8.6.2.6. South Africa Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. Regulatory Framework
    • 8.6.3.5. Reimbursement Scenario
    • 8.6.3.6. Saudi Arabia Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Competitive Scenario
    • 8.6.4.4. Regulatory Framework
    • 8.6.4.5. Reimbursement Scenario
    • 8.6.4.6. UAE Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Competitive Scenario
    • 8.6.5.4. Regulatory Framework
    • 8.6.5.5. Reimbursement Scenario
    • 8.6.5.6. Kuwait Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)

Chapter 9. Bloodstream Infection Testing Market: Competitive Landscape

• 8.1. Participant Categorization
  • 9.1.1. bioMerieux SA
    • 9.1.1.1. Overview
    • 9.1.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.1.1.3. Product Benchmarking
    • 9.1.1.4. Strategic Initiatives
  • 9.1.2. BD
    • 9.1.2.1. Overview
    • 9.1.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.1.2.3. Product Benchmarking
    • 9.1.2.4. Strategic Initiatives
  • 9.1.3. Cepheid
    • 9.1.3.1. Overview
    • 9.1.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.1.3.3. Product Benchmarking
    • 9.1.3.4. Strategic Initiatives
  • 9.1.4. Seegene Inc.
    • 9.1.4.1. Overview
    • 9.1.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.1.4.3. Product Benchmarking
    • 9.1.4.4. Strategic Initiatives
  • 9.1.5. T2 Biosystems, Inc.
    • 9.1.5.1. Overview
    • 9.1.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.1.5.3. Product Benchmarking
    • 9.1.5.4. Strategic Initiatives
  • 9.1.6. F. Hoffmann-La Roche Ltd
    • 9.1.6.1. Overview
    • 9.1.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.1.6.3. Product Benchmarking
    • 9.1.6.4. Strategic Initiatives
  • 9.1.7. Siemens Healthcare Limited
    • 9.1.7.1. Overview
    • 9.1.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.1.7.3. Product Benchmarking
    • 9.1.7.4. Strategic Initiatives
  • 9.1.8. Luminex Corporation
    • 9.1.8.1. Overview
    • 9.1.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.1.8.3. Product Benchmarking
    • 9.1.8.4. Strategic Initiatives
  • 9.1.9. Bruker
    • 9.1.9.1. Overview
    • 9.1.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.1.9.3. Product Benchmarking
    • 9.1.9.4. Strategic Initiatives
  • 9.1.10. Accelerate Diagnostics, Inc.
    • 9.1.10.1. Overview
    • 9.1.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.1.10.3. Product Benchmarking
    • 9.1.10.4. Strategic Initiatives
• 9.2. Participant's Overview
• 9.3. Financial Performance
• 9.4. Product Benchmarking
• 9.5. Company Market Share Analysis, 2022
• 9.6. Strategy Mapping
  • 9.6.1. Expansion
  • 9.6.2. Acquisition
  • 9.6.3. Product/Service Launch
  • 9.6.4. Others

Chapter 10. Analyst View